Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $11.15 up 1.64% from its previous closing price of $10.97. In other words, the price has increased by $1.64 from its previous closing price. On the day, 1.78 million shares were traded. SPRY stock price reached its highest trading level at $11.38 during the session, while it also had its lowest trading level at $11.0016.
Ratios:
For a deeper understanding of ARS Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.51 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.66.
On September 04, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $40.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $30.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 13 ’25 when Dorsey Brian sold 21,828 shares for $8.71 per share. The transaction valued at 190,050 led to the insider holds 10,789 shares of the business.
Chakma Justin sold 166,380 shares of SPRY for $1,476,147 on Nov 12 ’25. The Chief Business Officer now owns 0 shares after completing the transaction at $8.87 per share. On Nov 13 ’25, another insider, BRIAN T DORSEY, who serves as the Officer of the company, bought 21,828 shares for $8.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1102161920 and an Enterprise Value of 2085920000. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.72 while its Price-to-Book (P/B) ratio in mrq is 7.46. Its current Enterprise Value per Revenue stands at 14.61 whereas that against EBITDA is -23.227.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.79, which has changed by -0.040244997 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $6.66. The 50-Day Moving Average of the stock is 16.46%, while the 200-Day Moving Average is calculated to be -12.82%.
Shares Statistics:
For the past three months, SPRY has traded an average of 1.93M shares per day and 1532870 over the past ten days. A total of 98.84M shares are outstanding, with a floating share count of 59.73M. Insiders hold about 39.57% of the company’s shares, while institutions hold 63.76% stake in the company. Shares short for SPRY as of 1765756800 were 21588277 with a Short Ratio of 11.17, compared to 1763078400 on 20140227. Therefore, it implies a Short% of Shares Outstanding of 21588277 and a Short% of Float of 35.580003.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.49 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.74 and -$1.89 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$1.35, with 4.0 analysts recommending between -$0.92 and -$2.12.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $26.9M this quarter.It ranges from a high estimate of $32.9M to a low estimate of $21.8M. As of. The current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $86.58MFor the next quarter, 6 analysts are estimating revenue of $25.3M. There is a high estimate of $29M for the next quarter, whereas the lowest estimate is $21M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $89.1M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $83.05M. In the same quarter a year ago, actual revenue was $89.15MBased on 6 analysts’ estimates, the company’s revenue will be $181.73M in the next fiscal year. The high estimate is $226.7M and the low estimate is $151M.
